Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2026-04-13 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 85% confidence The document is a brief notice listing dates for the upcoming Annual Report, Half-yearly Report, AGM, and Quarterly Reports—it does not contain the reports themselves but announces their timing. This fits the definition of a Report Publication Announcement (RPA).
2026-04-13 English
Photocure ASA: Update on Regulatory Classification for OAY Equipment - Attachment: Release.pdf
Regulatory Filings Classification · 90% confidence The document is a stock exchange announcement disclosing FDA’s intention to reclassify a product code. It is not reporting financial results, management changes, dividends, share issues, or other specific categories but is a general regulatory update. As a catch-all for miscellaneous regulatory announcements, it falls under Regulatory Filings (RNS).
2026-04-13 English
Photocure ASA: Update on Regulatory Classification for OAY Equipment
Regulatory Filings Classification · 75% confidence The document is a stock exchange announcement (press release) regarding FDA’s planned reclassification of medical equipment, not a financial report, earnings release, or detailed presentation. It is a general regulatory announcement disclosing inside information under the Market Abuse Regulation, fitting the Regulatory Filings (RNS) category.
2026-04-13 English
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway - Attachment: Release.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA announcing their participation and presentation of 'trials in progress' at the European Association of Urology (EAU) 2026 congress. It details clinical trial information, scientific collaboration, and company product highlights. As it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is a general corporate announcement regarding company activities and scientific progress, it is classified as a Regulatory Filing (RNS).
2026-03-16 English
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA announcing their participation and the presentation of 'trials in progress' at the European Association of Urology (EAU) 2026 congress. It details clinical trial information, scientific collaboration, and company product highlights (Hexvix). As this is a general corporate announcement regarding company activities, clinical progress, and scientific events that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing/announcement.
2026-03-16 English
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions - Attachment: Release.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Photocure ASA regarding a regulatory milestone (drug approval) achieved by their partner, Asieris Pharmaceuticals. It provides details on the product, the clinical significance, and the financial implications (milestone payments). As it is a general corporate announcement regarding business operations and regulatory news that does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory announcement category.
2026-03-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.